Literature DB >> 15912276

Positron emission tomography imaging of small animals in anticancer drug development.

Eric O Aboagye1.   

Abstract

Positron emission tomography (PET) imaging of small animals enables researchers to bridge the gap between in vitro science and in vivo human studies. The imaging paradigm can be established and refined in animals before implementation in humans and image data related to ex vivo assays of biological activity. Small animal PET (saPET) imaging enables assessment of baseline focal pathophysiology, pharmacokinetics, biological target modulation and the efficacy of novel drugs. The potential and challenge of this technology as applied to anticancer drug development is discussed here.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15912276     DOI： 10.1007/s11307-005-0886-2

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN： 1536-1632            Impact factor:   3.488


  32 in total

Review 1.  The biological application of small animal PET imaging.

Authors:  R Myers
Journal:  Nucl Med Biol       Date:  2001-07       Impact factor: 2.408

Review 2.  Dedicated small animal scanners: a new tool for drug development?

Authors:  S P Hume; R Myers
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

3.  Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.

Authors:  J S Rasey; P D Hofstrand; L K Chin; T J Tewson
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

Review 4.  Apoptosis: the importance of nuclear medicine.

Authors:  F G Blankenberg; J Tait; K Ohtsuki; H W Strauss
Journal:  Nucl Med Commun       Date:  2000-03       Impact factor: 1.690

5.  Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography.

Authors:  A Saleem; R J Harte; J C Matthews; S Osman; F Brady; S K Luthra; G D Brown; N Bleehen; T Connors; T Jones; P M Price; E O Aboagye
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

6.  Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.

Authors:  A Saleem; J Yap; S Osman; F Brady; B Suttle; S V Lucas; T Jones; P M Price; E O Aboagye
Journal:  Lancet       Date:  2000-06-17       Impact factor: 79.321

7.  The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography.

Authors:  David R Collingridge; Veronica A Carroll; Mathias Glaser; Eric O Aboagye; Safiye Osman; Oliver C Hutchinson; Henryk Barthel; Sajinder K Luthra; Frank Brady; Roy Bicknell; Pat Price; Adrian L Harris
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

8.  Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells.

Authors:  J Boren; M Cascante; S Marin; B Comín-Anduix; J J Centelles; S Lim; S Bassilian; S Ahmed; W N Lee; L G Boros
Journal:  J Biol Chem       Date:  2001-08-06       Impact factor: 5.157

9.  [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?

Authors:  Karoline Spaepen; Sigrid Stroobants; Patrick Dupont; Guy Bormans; Jan Balzarini; Gregor Verhoef; Luc Mortelmans; Peter Vandenberghe; Christine De Wolf-Peeters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-25       Impact factor: 9.236

10.  Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene.

Authors:  Thomas Groot-Wassink; Eric O Aboagye; Matthias Glaser; Nicholas R Lemoine; Georges Vassaux
Journal:  Hum Gene Ther       Date:  2002-09-20       Impact factor: 5.695
View more
  6 in total

1.  Evaluation of the Genisys4, a bench-top preclinical PET scanner.

Authors:  Ken Herrmann; Magnus Dahlbom; David Nathanson; Liu Wei; Caius Radu; Arion Chatziioannou; Johannes Czernin
Journal:  J Nucl Med       Date:  2013-04-29       Impact factor: 10.057

2.  Quantification and MRI validation of regional contractile dysfunction in mice post myocardial infarction using high resolution ultrasound.

Authors:  Yinbo Li; Christopher D Garson; Yaqin Xu; Ronald J Beyers; Frederick H Epstein; Brent A French; John A Hossack
Journal:  Ultrasound Med Biol       Date:  2007-04-16       Impact factor: 2.998

3.  Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.

Authors:  Jeffrey R Tseng; Darrin Stuart; Kimberly Aardalen; Angelo Kaplan; Natasha Aziz; Nicholas P Hughes; Sanjiv S Gambhir
Journal:  Neoplasia       Date:  2011-03       Impact factor: 5.715

4.  Assessment of S values in stylized and voxel-based rat models for positron-emitting radionuclides.

Authors:  Tianwu Xie; Habib Zaidi
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

5.  Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.

Authors:  Kawai Yau; Patricia Price; Radhakrishma G Pillai; Eric Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

Review 6.  Translational molecular imaging for cancer.

Authors:  Martin G Pomper
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.